We are live on ! Find out more

2,392 hedge funds and large institutions have $173B invested in Pfizer in 2019 Q1 according to their latest regulatory filings, with 132 funds opening new positions, 906 increasing their positions, 1,113 reducing their positions, and 111 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more first-time investments, than exits

New positions opened: 132 | Existing positions closed: 111

19% more call options, than puts

Call options by funds: $1.53B | Put options by funds: $1.29B

1.62% more ownership

Funds ownership: 75.91%77.53% (+1.6%)

0% less funds holding

Funds holding: 2,4042,392 (-12)

4% less capital invested

Capital invested by funds: $180B → $173B (-$6.79B)

19% less repeat investments, than reductions

Existing positions increased: 906 | Existing positions reduced: 1,113

38% less funds holding in top 10

Funds holding in top 10: 328202 (-126)

Holders
2,392
Holders Change
-12
Holders Change %
-0.5%
% of All Funds
51.76%
Holding in Top 10
202
Holding in Top 10 Change
-126
Holding in Top 10 Change %
-38.41%
% of All Funds
4.37%
New
132
Increased
906
Reduced
1,113
Closed
111
Calls
$1.53B
Puts
$1.29B
Net Calls
+$241M
Net Calls Change
+$316M
Name Holding Trade Value Shares
Change
Change in
Stake
BCM
226
Becker Capital Management
Oregon
$56.6M -$5.03M -125,596 -8%
SC
227
Scotia Capital
Ontario, Canada
$56M +$2.16M +54,010 +4%
EDRH
228
Edmond de Rothschild Holding
Switzerland
$55.5M -$3.17M -79,166 -5%
SCM
229
Suvretta Capital Management
New York
$54.4M +$52.5M +1,312,019 +3,557%
PP
230
Paloma Partners
Connecticut
$53.9M +$39.9M +995,569 +291%
AAM
231
Advisors Asset Management
Colorado
$53.8M -$6.14M -153,244 -10%
ERSOT
232
Employees Retirement System of Texas
Texas
$53.5M -$1.05M -26,224 -2%
MSE
233
MUFG Securities EMEA
United Kingdom
$53.4M +$22.4M +560,306 +73%
Nomura Asset Management
234
Nomura Asset Management
Japan
$52.8M -$6.1M -152,369 -10%
Brown Advisory
235
Brown Advisory
Maryland
$51.5M -$1.59M -39,679 -3%
MNG
236
Manning & Napier Group
New York
$51.2M +$10.7M +266,222 +26%
SC
237
Saturna Capital
Washington
$51.1M +$313K +7,818 +0.6%
KCM
238
Kornitzer Capital Management
Kansas
$51.1M +$91.3K +2,281 +0.2%
Voloridge Investment Management
239
Voloridge Investment Management
Florida
$51M +$50.7M +1,265,558 New
SBH
240
Segall Bryant & Hamill
Illinois
$50.8M -$526K -13,135 -1%
BNP Paribas Asset Management
241
BNP Paribas Asset Management
France
$50.4M +$1.36M +33,840 +3%
ASRS
242
Arizona State Retirement System
Arizona
$49.8M -$5.35M -133,571 -10%
Los Angeles Capital Management
243
Los Angeles Capital Management
California
$49.6M -$4.61M -115,223 -9%
CI Investments Inc
244
CI Investments Inc
Ontario, Canada
$49.4M -$83.3M -2,081,030 -63%
CI
245
Conning Inc
Connecticut
$48.9M +$1.23M +30,837 +3%
CIBC Private Wealth Group
246
CIBC Private Wealth Group
Georgia
$48.9M +$1.71M +42,627 +4%
ProShare Advisors
247
ProShare Advisors
Maryland
$48.6M +$118K +2,953 +0.2%
CIBC World Market
248
CIBC World Market
Ontario, Canada
$48.6M -$45.3M -1,131,460 -48%
EPFB
249
Employees Provident Fund Board
Malaysia
$47.9M
TH
250
TCTC Holdings
Texas
$46.6M -$4.17K -104 -0%

PFE Hedge Fund Activity: Q1 2019 in Review

2,392 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q1 2019, worth a combined $173B — down 3.8% from $180B a quarter earlier.

Buyers outnumbered sellers: 132 funds opened new PFE positions and 111 closed out — a net gain of 21 holders — while 906 added to existing stakes and 1,113 trimmed.

The largest buyer was Capital World Investors, adding an estimated $967M. The largest seller was BlackRock, cutting an estimated $715M.

  • 2,392 institutional investors held Pfizer (PFE) as of Q1 2019, down from 2,404 in Q4 2018.
  • Funds reported $173B of Pfizer stock for Q1 2019, down 3.8% quarter-over-quarter.
  • 132 funds opened new Pfizer positions in Q1 2019 and 111 closed out, a net change of +21 holders.
  • The largest Pfizer buyer in Q1 2019 was Capital World Investors, an estimated $967M added.
  • The largest Pfizer seller in Q1 2019 was BlackRock, an estimated $715M sold.

Based on aggregated 13F filings for Q1 2019.